{"id":743982,"date":"2020-03-20T17:01:00","date_gmt":"2020-03-20T17:01:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/"},"modified":"2025-03-07T23:37:34","modified_gmt":"2025-03-08T04:37:34","slug":"merck-recommends-rejection-of-trc-capitals-mini-tender-offer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/","title":{"rendered":"Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer"},"content":{"rendered":"<div class=\"q4default\">\n<p>    KENILWORTH, N.J.&#8211;(BUSINESS WIRE)&#8211;<br \/>\nMerck &amp; Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited \u201cmini-tender\u201d offer, dated March 26, 2020, to purchase up to 1,500,000 shares of Merck common stock at $73.35 per share. The offer price is approximately 4.4% below the closing price of the Merck common stock on March 13, 2020 ($76.75), the last trading day before the date of the offer, but approximately 2.8% above the closing price of the Merck common stock today March 20, 2020 ($71.36).\n<\/p>\n<p>\nMerck does not endorse TRC Capital\u2019s offer and recommends that Merck shareholders reject the offer and not tender their shares in response to TRC Capital\u2019s unsolicited mini-tender offer. This mini-tender offer is at a price below the closing price for Merck\u2019s shares (as of the day prior to the offer) and is subject to numerous conditions, including TRC Capital\u2019s ability to obtain financing, there being no decrease to the market price of the Merck common stock since March 16, 2020, and no material worsening of the COVID-19 pandemic since March 13, 2020. Merck is not associated in any way with TRC Capital, its mini-tender offer or the offer documentation.\n<\/p>\n<p>\nTRC Capital has made similar, unsolicited mini-tender offers for shares of other publicly traded companies. Mini-tender offers seek to acquire less than five percent of a company&#8217;s outstanding shares. This lets the offering company avoid many of the disclosure and procedural requirements the U.S. Securities and Exchange Commission (SEC) requires for tender offers. As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under the U.S. federal securities laws.\n<\/p>\n<p>\nOn its <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2Ffast-answers%2Fanswersminitenhtm.html&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=82bb9cdf5b5e880660756d0c88f64361\">website<\/a>, the SEC advises that the people behind mini tender-offers \u201cfrequently use mini-tender offers to catch shareholders off guard\u201d and that investors \u201cmay end up selling at below-market prices.\u201d The SEC&#8217;s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2Freportspubs%2Finvestor-publications%2Finvestorpubsminitendhtm.html&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=website&amp;index=2&amp;md5=5f3cc65fafbe196b533304a837e15600\">website<\/a> also contains important tips for investors regarding mini-tender offers.\n<\/p>\n<p>\nLike TRC Capital\u2019s other offers, this one puts individual investors at risk because they may sell their shares at a discount without so realizing. Merck urges shareholders to obtain current stock quotes for their shares of Merck common stock, review the terms and conditions to the offer, consult with their broker or financial adviser and exercise caution with respect to TRC Capital\u2019s mini-tender offer.\n<\/p>\n<p>\nMerck shareholders who have already tendered are advised that they may withdraw their shares by providing the written notice described in the TRC Capital offering documents prior to the expiration of the offer, which is currently scheduled at 12:01 a.m. New York City time on Wednesday, April 15, 2020.\n<\/p>\n<p>\nMerck encourages brokers, dealers, and other investors to review the SEC\u2019s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2Fdivisions%2Fmarketreg%2Fminitenders%2Fsia072401.htm&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=letter&amp;index=3&amp;md5=f504dd227ead42bbe61b7d205c20c670\">letter<\/a> regarding broker-dealer mini-tender offer dissemination and disclosure.\n<\/p>\n<p>\nMerck requests that a copy of this news release be included with all distribution of materials related to TRC Capital\u2019s offer for shares of Merck common stock.\n<\/p>\n<p>\n  <b>About Merck<\/b>\n<\/p>\n<p>\nFor more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals \u2013 including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases \u2013 as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=bffbfcab6cca6d8f8f58a0344208ba22\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=702383622d8c9891713f0b6e55e9ae2b\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=5c64a894dcd45af86465b0ffcafe47f7\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=27f424821979aea6616f2dff72147396\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=31cb4637d83c3d279f1e2a2235198be8\">YouTube<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=4b2514dec463f6e8366f61c972e82a7a\">LinkedIn<\/a>.\n<\/p>\n<p>\n  <b>Forward-Looking Statement<\/b>\n<\/p>\n<p>\nThis news release of Merck may include \u201cforward-looking statements.\u201d These statements are based upon the current beliefs and expectations of Merck\u2019s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n<p>\nMerck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck\u2019s 2019 Annual Report on Form 10-K and Merck\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52190856&amp;newsitemid=20200320005578&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=0371cac3166639b07c2241add44e200a\">www.sec.gov<\/a>).\n<\/p>\n<p>\n  <img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n  <span class=\"bwct31415\"><\/span>\n<\/p>\n<p id=\"mmgallerylink\">\n  <span id=\"mmgallerylink-phrase\">View source version on <a href=\"http:\/\/businesswire.com\">businesswire.com<\/a>: <\/span><br \/>\n  <span id=\"mmgallerylink-link\"><br \/>\n    <a href=\"https:\/\/www.businesswire.com\/news\/home\/20200320005578\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20200320005578\/en\/<\/a><br \/>\n  <\/span>\n<\/p>\n<p>\nMedia:<br \/>\n<br \/>Jennifer Mauer<br \/>\n<br \/>(908) 740-1801\n<\/p>\n<p>\nInvestors:<br \/>\n<br \/>Peter Dannenbaum<br \/>\n<br \/>(908) 740-1037\n<\/p>\n<p>\nMichael DeCarbo<br \/>\n<br \/>(908) 740-1807\n<\/p>\n<p>Source: Merck &amp; Co., Inc.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited \u201cmini-tender\u201d offer, dated March 26, 2020, to purchase up to 1,500,000 shares of Merck common stock at $73.35 per share. The offer price is approximately 4.4% below the closing price of the Merck common stock on March 13, 2020 ($76.75), the last trading day before the date of the offer, but approximately 2.8% above the closing price of the Merck common stock today March 20, 2020 ($71.36). Merck does not endorse TRC Capital\u2019s offer and recommends that Merck shareholders reject the offer and not tender their shares in response to TRC Capital\u2019s unsolicited mini-tender offer. This mini-tender offer is at a price below the closing price for Merck\u2019s shares (as of the day prior to the offer) and is subject to numerous conditions, including TRC Capital\u2019s ability to obtain financing, there being no decrease to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-743982","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited \u201cmini-tender\u201d offer, dated March 26, 2020, to purchase up to 1,500,000 shares of Merck common stock at $73.35 per share. The offer price is approximately 4.4% below the closing price of the Merck common stock on March 13, 2020 ($76.75), the last trading day before the date of the offer, but approximately 2.8% above the closing price of the Merck common stock today March 20, 2020 ($71.36). Merck does not endorse TRC Capital\u2019s offer and recommends that Merck shareholders reject the offer and not tender their shares in response to TRC Capital\u2019s unsolicited mini-tender offer. This mini-tender offer is at a price below the closing price for Merck\u2019s shares (as of the day prior to the offer) and is subject to numerous conditions, including TRC Capital\u2019s ability to obtain financing, there being no decrease to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-08T04:37:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\\\/\",\"name\":\"Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-03-20T17:01:00+00:00\",\"dateModified\":\"2025-03-08T04:37:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/","og_locale":"en_US","og_type":"article","og_title":"Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer - Merck.com","og_description":"Merck &amp; Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited \u201cmini-tender\u201d offer, dated March 26, 2020, to purchase up to 1,500,000 shares of Merck common stock at $73.35 per share. The offer price is approximately 4.4% below the closing price of the Merck common stock on March 13, 2020 ($76.75), the last trading day before the date of the offer, but approximately 2.8% above the closing price of the Merck common stock today March 20, 2020 ($71.36). Merck does not endorse TRC Capital\u2019s offer and recommends that Merck shareholders reject the offer and not tender their shares in response to TRC Capital\u2019s unsolicited mini-tender offer. This mini-tender offer is at a price below the closing price for Merck\u2019s shares (as of the day prior to the offer) and is subject to numerous conditions, including TRC Capital\u2019s ability to obtain financing, there being no decrease to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/","og_site_name":"Merck.com","article_modified_time":"2025-03-08T04:37:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/","name":"Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en","datePublished":"2020-03-20T17:01:00+00:00","dateModified":"2025-03-08T04:37:34+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200320005578r1&amp;sid=q4web&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-recommends-rejection-of-trc-capitals-mini-tender-offer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Recommends Rejection of TRC Capital\u2019s \u201cMini-Tender\u201d Offer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"10009700-9fa0-4feb-b867-c2618dfa9257","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_multimedia\/merck_logo.jpg","size":"13027","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Recommends-Rejection-of-TRC-Capitals-Mini-Tender-Offer-2020.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743982\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743982"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}